IL-25 Regulates the Expression of Adhesion Molecules on Eosinophils: Mechanism of Eosinophilia in Allergic Inflammation
Overview
Authors
Affiliations
Background: Interleukin-25 (IL-25) is a novel T-helper-2 (Th2) cytokine of the IL-17 family that plays a key role in allergic inflammation. Recent studies reported that over-expression of IL-25 in mouse induces eosinophilia. We investigated the effect of IL-25 on the expression of several adhesion molecules on human eosinophils and the underlying intracellular mechanisms.
Methods: Viability of eosinophils was measured by annexin V-fluorescein isothiocyanate (FITC) assay. Gene expression and surface expression of intercellular adhesion molecule (ICAM)-1 (CD54), ICAM-3 (CD50), L-selectin (CD62L), leukocyte function-associated antigen (LFA-1) (CD11a/CD18) and very late antigen-4 (VLA-4, CD49d/CD29) on eosinophils were measured by reverse transcriptase-polymerase chain reaction (RT-PCR) and flow cytometry, respectively. Adhesion of eosinophils to fibronectin was assessed using the fibronectin-coated insert system.
Results: Viability of eosinophils was significantly enhanced by IL-25 from 41% to 76% dose-dependently. IL-25 could significantly upregulate the surface expression of ICAM-1, but suppress those of ICAM-3 and L-selectin on eosinophils in a dose-dependent manner. Adhesion of eosinophils to fibronectin was also significantly enhanced by IL-25. Besides, pre-incubation with p38 mitogen-activated protein kinases (MAPK) inhibitor SB203580, C-Jun NH2-terminal protein kinases (JNK) inhibitor SP600125 and proteosome inhibitor MG-132 could significantly restrain the effects of IL-25 on surface expression of L-selectin, ICAM-1 and ICAM-3, respectively, and also on the adhesion of eosinophils onto fibronectin (all P < 0.05).
Conclusions: Our findings suggest an essential role of IL-25 in enhancing survival and regulating surface expression of ICAM-1, ICAM-3 and L-selectin on human eosinophils through the activation of p38 MAPK, JNK and nuclear factor (NF)-kappaB pathways, thereby shedding light on the molecular mechanisms of IL-25-induced eosinophilia in allergic inflammation.
Xu G, Paglialunga S, Qian X, Ding R, Webster K, van Haarst A Front Immunol. 2024; 15():1495540.
PMID: 39717777 PMC: 11663749. DOI: 10.3389/fimmu.2024.1495540.
Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets.
Hansi R, Ranjbar M, Whetstone C, Gauvreau G Biomedicines. 2024; 12(10).
PMID: 39457624 PMC: 11505104. DOI: 10.3390/biomedicines12102312.
Update on Inflammatory Biomarkers for Defining Asthma Phenotype.
Sim S, Choi Y, Park H Allergy Asthma Immunol Res. 2024; 16(5):462-472.
PMID: 39363766 PMC: 11450439. DOI: 10.4168/aair.2024.16.5.462.
Upper Airway Alarmin Cytokine Expression in Asthma of Different Severities.
Marriott H, Duchesne M, Moitra S, Okoye I, Gerla L, Mayers I J Clin Med. 2024; 13(13).
PMID: 38999286 PMC: 11242732. DOI: 10.3390/jcm13133721.
Sounding the alarmins-The role of alarmin cytokines in asthma.
Gauvreau G, Bergeron C, Boulet L, Cockcroft D, Cote A, Davis B Allergy. 2022; 78(2):402-417.
PMID: 36463491 PMC: 10108333. DOI: 10.1111/all.15609.